Loose Skin After GLP-1 Weight Loss: How to Protect Muscle and Plan Body Contouring

How much weight do GLP-1 medications help people lose?

The results are substantial, but they need context. Liraglutide 3.0 mg produced an average 8.0% reduction at 56 weeks in the SCALE trial. Semaglutide 2.4 mg produced an average 14.9% reduction at 68 weeks in STEP 1. Tirzepatide produced average reductions of 19.5% with 10 mg and 20.9% with 15 mg at 72 weeks in SURMOUNT-1.^1–3

Retatrutide, an investigational triple agonist, produced a reported average 28.3% reduction with 12 mg at 80 weeks in the 2026 TRIUMPH-1 topline announcement. It remains investigational and is not an approved weight-management medication. Regulatory timing can change.⁴

Use the correct international drug names

What does the scale fail to show during weight loss?

Body weight can change because of fat, lean tissue, water, glycogen and other tissues. “Lean mass” is not the same as skeletal muscle: it also includes water, organs and other non-fat tissue. A body-composition device cannot perfectly separate every compartment either, especially when hydration changes.

• Fat massThe primary tissue most patients intend to reduce.
• Lean tissueIncludes more than skeletal muscle.
• WaterCan shift rapidly and affect measurements.
• Stored energyGlycogen changes are linked with water change.

If appetite suppression greatly reduces the quantity and variety of food, some patients may struggle to obtain enough protein or micronutrients. This does not mean that the medication directly “drains” a specific vitamin or mineral. The concern is inadequate intake, persistent gastrointestinal symptoms or an existing deficiency that becomes harder to correct.⁵

Track the trend, not one isolated reading: weight and waist change, repeated body-composition measurements under similar conditions, actual strength, exercise performance, food and fluid intake, fatigue, dizziness, hair shedding and gastrointestinal symptoms.

Are muscle-preserving obesity medications being developed?

Yes—but they are investigational. In a 2026 phase 2 trial, adding bimagrumab, an activin type II receptor antibody, to semaglutide reduced the loss of lean mass compared with semaglutide alone. Another phase 2 trial found 1.9 kg less lean-mass loss at 24 weeks when the myostatin-targeting antibody apitegromab was added to tirzepatide.^6,7

These studies do not mean that an approved “zero muscle loss” obesity medication is available. Lean-mass preservation is also not identical to proven improvement in long-term strength, mobility or safety. What they do show is an important change in research: future treatment quality may be judged by how much fat is lost, what function is preserved and how well the result is maintained—not by body weight alone.

Why can the face and body look looser after GLP-1 weight loss?

“Ozempic face” is a popular phrase, not a medical diagnosis. It describes facial hollowing, visible wrinkles or laxity that may become more noticeable when facial fat and soft-tissue volume decrease. It is not unique to Ozempic or semaglutide; similar changes can follow substantial weight loss by other methods.⁸

Loose skin is not explained by speed alone. The total amount of weight lost, age, inherited skin elasticity, how long the tissue was stretched, repeated weight cycling, pregnancy, smoking, sun exposure and the support from underlying tissue all matter. Patients who begin at a higher weight often lose a larger total volume and may have had stretched tissue for longer, increasing the chance that structural excess skin will remain.

What is Dr. Jeon’s Clinical Soft-Landing Framework?

Since 2009, I have repeatedly seen patients reach an impressive number quickly and then face a second set of concerns: loss of strength, facial volume change, hair shedding, difficulty maintaining intake, or excess skin around the chest, abdomen, arms and thighs.

I have also used a GLP-1–based medication myself for about two years, adjusting my treatment plan as my weight, appetite, physical condition, exercise and maintenance goals changed. That experience helped me understand both the value of the medication and the temptation to chase a faster result.

My Clinical Soft-Landing Framework combines that personal perspective with body-contouring experience. It is designed to move from active weight loss into a maintainable landing rather than treating the lowest possible number as the finish line.

What do 5% and 2% mean for a 100 kg (220 lb) patient?

• 5% = 5 kg (11 lb)This is not a required monthly target. Repeatedly exceeding it prompts reassessment in Dr. Jeon’s framework.
• 2% = 2 kg (4.4 lb)This calculation illustrates the landing concept. The actual percentage is calculated from the patient’s current weight at that stage.

A meta-analysis comparing similar total weight loss found that gradual loss favored fat-mass reduction and preservation of resting metabolic rate, but did not find a significant difference in fat-free-mass change. That does not prove that losing slowly will preserve muscle or prevent loose skin in the long term.⁹

Medication dose or timing should never be changed to match these percentages without the prescribing clinician. They are a conversation framework, not a self-treatment protocol.

Will weight return after stopping a GLP-1 medication?

Weight regain is common after treatment stops, but there is no reliable universal rule that “half regain and half do not.” In the STEP 1 extension, participants regained about two-thirds of their previous semaglutide-associated weight loss on average during the year after withdrawal. That refers to the average amount regained, not the percentage of patients who failed, and it does not mean that every participant returned to baseline.¹⁰

Regain is influenced by appetite biology, lower energy requirements after weight loss, the treatment plan, food environment, sleep, stress, activity, strength, follow-up and whether another maintenance strategy is used. Obesity is a chronic disease. Some patients may need long-term medication or another ongoing strategy; regain is not proof of weak willpower.

There is encouraging evidence for planning exercise early. In a randomized trial and one-year post-treatment follow-up, participants who combined liraglutide with supervised exercise maintained weight and body composition better after treatment ended than those who received liraglutide alone.¹¹ The study did not prove that an increase in basal metabolic rate was the single reason, and exercise does not guarantee zero regain.

What if significant loose skin is already present?

Mild laxity may look somewhat better after weight stabilizes and the underlying muscle frame improves. Skin also needs time after a major change. However, exercise, creams and medication cannot directly remove a substantial structural fold of excess skin.

When loose skin remains significant, skin-excision body contouring is a treatment that can remove it directly. Depending on the area, options may include:

Not everyone with loose skin needs surgery. A longer scar corrects a broader area but creates a larger wound and recovery burden. Some multi-area procedures are safer when staged rather than performed together.

When is the right time for skin-removal surgery?

The American Society of Plastic Surgeons Practice Parameter describes body-contouring surgery as ideally performed after stable weight has been maintained for two to six months. Evita Clinic generally advises about six months of stable weight before planning elective skin-removal surgery. A larger loss, bariatric surgery, continuing medication adjustment or incomplete recovery preparation may require a longer wait.¹²

Time alone is not enough. The active loss phase should be substantially complete, the current weight should be maintainable, and the patient should be prepared for the scar, recovery and—when necessary—a staged plan. Functional problems such as recurrent dermatitis, hygiene difficulty or impaired movement may change the priority and require individualized assessment.

Do GLP-1 medications have to be stopped before surgery?

Not automatically. Recommendations differ by country and institution. A 2024 US multi-society clinical guidance allows many patients without elevated delayed-gastric-emptying or aspiration risk to continue treatment, while emphasizing shared risk assessment. UK guidance also supports continuation with risk mitigation. A 2025 Australian and New Zealand recommendation supports continuation and recommends a 24-hour clear-fluid diet for all GLP-1 or GLP-1/GIP users before procedures involving anesthesia or sedation.^13–15

Tell the prescribing clinician and Evita surgical team the exact medication, dose, schedule, last dose, recent dose escalation, gastrointestinal symptoms and whether it is used for diabetes. The decision to continue, pause and restart medication must follow the current surgical protocol and the individual plan—not a blog post.